Obesity compounds the metabolic response to critical illness and increases the risk for overfeeding complications due to its comorbidities. Hypocaloric, high-protein nutrition therapy affords the hospitalized patient with obesity the opportunity to achieve net protein anabolism with a reduced risk of overfeeding complications. The intent of this review is to provide the theoretical framework for development of a hypocaloric high-protein regimen, scientific evidence to support this mode of therapy, and unique considerations for its use in specialized subpopulations. 
Invited Review
Recent data from the National Health and Nutrition Examination Survey (NHANES) indicate that nearly half (43%) of adults in the United States are obese. 1, 2 Greater than 25% of intensive care unit (ICU) patients are obese, as defined by a body mass index (BMI) >30 kg/m 2 . 3, 4 Unfortunately, the obesity epidemic has expanded beyond the United States and has become a global issue. 5 Contrary to common erroneous belief among uninformed clinicians, critically ill patients with obesity and caloric abundance require nutrition therapy in an effort to optimize wound healing; to provide substrate to mount an effective response to critical illness, surgery, or trauma; and to recover from the ill effects (eg, muscle weakness) of their hospitalization. However, the presence of obesity is associated with numerous metabolic complications that directly interface with nutrition support therapy. As a result, hospitalized patients with obesity may require a different nutrient prescription than their nonobese counterparts. Careful monitoring techniques to evaluate the safety and efficacy of the prescribed metabolic support regimen in the critically ill obese patient are of paramount importance. The intent of this review is to provide the theoretical framework for development of a hypocaloric high-protein regimen, scientific evidence to support this mode of therapy, and unique considerations for its use in specialized subpopulations.
Consequences of Obesity That Compound Critical Illness and Nutrition Therapy
Nutrition assessment of the obese patient is challenging as conventional physical assessment techniques are not precise. One particular detriment to achieving positive clinical outcomes is the presence of sarcopenia. Sarcopenic obesity is the presence of an abundance of body fat with concurrent reduced muscle mass. 6 Unfortunately, sarcopenia is difficult to detect in sarcopenic obesity as traditional physical assessment methods are limited by the presence of excessive body fat. 6 Limited physical activity or impaired mobility prior to hospitalization or advanced age may provide a strong clue to the presence of sarcopenia. Detection of sarcopenia in obese patients is important as its presence has been associated with detrimental clinical outcomes, including poorer functional status, dysglycemia, higher incidence of chemotherapy toxicity, and worsened survival. [7] [8] [9] Lack of nutrition therapy for hospitalized patients with obesity may be detrimental to clinical outcomes (eg, wound healing, functional status, survival) as patients with obesity have a higher protein turnover and greater catabolism rate than those without obesity. 10 The etiology for this exaggerated protein catabolism has been attributed to obesity-associated insulin resistance altering the anabolic effect of insulin on protein synthesis. 10 In developing a
nutrition support plan for the critically ill patient with obesity, it may be necessary to modify the regimen based on the presence of obesity-associated comorbidities. Overfeeding the patient with obesity may be common due to the inaccuracy of predictive methods in estimating energy expenditure. 11 The greatest concern is not to overfeed (by providing a caloric intake significantly greater than total energy expenditure) the obese patient as complications extend beyond a simple amplification of abundant caloric reserves. Patients who are overweight or obese may be insulin resistant. 12 Critically ill patients with infections or injuries experience a postreceptor insulin resistance and increased cortisol and catecholamine production, which also results in hyperglycemia. 13 Thus, when obesity, critical illness, and a carbohydrate-containing nutrition therapy are combined, hyperglycemia is a prevalent complication that requires vigilant management. 14 Hypertriglyceridemia is also more prevalent in patients with obesity than in the nonobese. 15 Severe hypertriglyceridemia can impair reticuloendothelial system clearance, cause hepatic fat accumulation, and potentially induce acute pancreatitis. For patients who exhibit combined hyperglycemia and hypertriglyceridemia and have insulin-dependent diabetes mellitus, improvement in glycemic control may improve hypertriglyceridemia 16 and allow for the safe administration of intravenous (IV) fat emulsion. However, impaired IV fat emulsion clearance and hypertriglyceridemia may persist, irrespective of glycemic control, especially in noninsulin-dependent patients with diabetes mellitus. 16 Other consequences of obesity that may be detrimentally influenced by overfeeding are duration of mechanical ventilation 17 and nonalcoholic fatty liver disease. 18 Caloric overfeeding can result in worsening hypercapnia 19 as well as hepatic steatosis. 18, 20 Thus, overfeeding must be avoided in the obese patient with metabolic complications.
Development of a Macronutrient Prescription
A wide variability and lack of precision with predicting energy expenditure for estimating caloric requirements make it nearly impossible to avoid overfeeding in the hospitalized obese patient. 11 This inaccuracy is due to differing amounts of muscle mass as well as presence of diseases and conditions of hospitalized patients that can variably increase or decrease energy expenditure. The gold standard for estimating energy expenditure is indirect calorimetry (IC). If IC is unavailable, as it is in many centers, energy expenditure may be estimated by the Penn State or Mifflin-St Jeor equations. [21] [22] [23] However, the precision of these equations is limited. Current guidelines suggest the use of hypocaloric, high-protein nutrition therapy for patients with obesity in an effort to preserve lean body mass, mobilize adipose stores, and minimize potential overfeeding complications. 11, 24 Others 25,26 pioneered the concept that energy and protein should be considered separately in designing feeding regimens depending on the desired body composition outcome goals. The concept of hypocaloric high-protein nutrition therapy was derived from studies that indicated attainment of a positive nitrogen balance without excessive energy intake. The relation between calorie and protein intake and their combined effect on nitrogen balance in unstressed, depleted patients is depicted in Figure 1 . The figure illustrates that positive nitrogen balance or nitrogen equilibrium can be achieved with a low-calorie, high-protein regimen (points A and B); a moderate-calorie, moderate-protein regimen (point C); or a high-calorie, lowprotein regimen (point D). However, despite similar nitrogen balances, different changes in body composition would be anticipated with these diverse macronutrient regimens. 27 The low-calorie, high-protein regimens would likely result in a gain of lean body mass with loss of body fat, whereas the highcalorie, low-protein regimen would lead to a gain in body fat with potential loss of lean body mass. 27 During critical illness, the calorie-protein interaction/effect upon nitrogen balance and its influence on body composition is altered. Critically ill patients generally experience marked protein catabolism, which can be reduced with nutrition therapy but will not be completely abated until the stress response dissipates. [28] [29] [30] Total-body protein content declines during critical illness during nutrition therapy; however, the rate of net Figure 1 . Interaction of calorie and protein intake upon nitrogen balance in unstressed depleted patients. The dashed lines represent protein intakes that could achieve net protein anabolism during hypocaloric nutrition therapy. Points A and B illustrate achievement of nitrogen equilibrium at caloric intakes less than energy expenditure when given higher protein intakes, whereas point C indicates nitrogen equilibrium with a lesser protein intake and with a greater caloric intake, and point D reflects nitrogen equilibrium with a low protein intake but with a markedly increased caloric intake. protein catabolism and total body protein loss is reduced compared with receipt of nonnutritional IV fluids. 29, 30 Increases in caloric intake from 82% to 118% to 148% of measured resting energy expenditure, without an increase in protein intake, did not improve the negative nitrogen balance or urinary 3-methylhistidine excretion (a marker of muscle proteolysis) in critically ill trauma patients given isonitrogenous parenteral nutrition (PN) regimens at a protein intake of ~1.7 g/kg/d. 31 In addition, excessive caloric delivery above 1.2 times measured resting energy expenditure has been demonstrated to significantly increase body fat mass without further attenuating erosion of lean body mass in thermally injured patients. 32 These data suggest that significant increases in nonprotein calories are ineffective in substantially improving nitrogen balance or body protein catabolism.
Evidence for the Use of Hypocaloric HighProtein Nutrition Therapy in Obesity
The interaction between calories and protein upon nitrogen balance and body composition, in conjunction with vigilance in avoiding overfeeding complications, serves as the basis for the use of hypocaloric, high-protein nutrition therapy for the hospitalized patient with obesity. Table 1 summarizes the current literature of 6 comparative studies and 2 case series totaling 226 hospitalized, surgical, and trauma obese patients receiving hypocaloric, high-protein nutrition support therapy. 12, [33] [34] [35] [36] [37] [38] [39] Mean protein intakes ranged from 1.5 g/kg ideal body weight (IBW)/d to 2.2 g/kg IBW/d for all patients with caloric intakes ranging from 18-25 kcal/kg IBW/d and 30-42 kcal/kg IBW/d for those receiving hypocaloric vs eucaloric feeding, respectively. Most patients achieved nitrogen equilibrium or positive nitrogen balance except in the critically ill trauma patient population, wherein both hypocaloric and eucaloric nutrition therapy groups exhibited a mean negative nitrogen balance. 35, 36 One randomized controlled trial indicated a trend toward decreased insulin requirements for those given a hypocaloric, high-protein regimen compared with eucaloric, high-protein feeding. 34 Mean serum glucose concentration ranged from 140-175 mg/dL for the hypocaloric group to 175-220 mg/dL for the eucaloric group. 34 However, it is difficult to evaluate these findings given that this study was performed prior to our current knowledge of the importance of more rigorous glycemic control upon clinical outcomes for critically ill patients. 40 Significantly improved clinical outcomes, as evidenced by decreased length of ICU stay, decreased duration of antibiotic therapy, and a trend toward decreased ventilator days and hospital length of stay, were suggested in a small retrospective study comparing hypocaloric, high-protein enteral nutrition (EN) therapy to eucaloric, high-protein diets in obese critically ill trauma patients. 35 This outcome was unanticipated given that all previous studies (Table 1 ) had indicated no difference in clinical outcomes between hypocaloric and eucaloric feeding groups. A large, prospective randomized controlled trial to define optimal caloric requirement during high-protein therapy in the critically ill obese patient is warranted.
The 2013 American Society for Parenteral and Enteral Nutrition (ASPEN) nutrition support guidelines of the hospitalized adult patient with obesity 11 state that clinical outcomes are at least equivalent, if not improved, by the provision of hypocaloric feeding when adequate protein intake is given to achieve net protein anabolism. The 2016 ASPEN-Society of Critical Care Medicine (SCCM) nutrition support guidelines in the adult critically ill patient 24 concur with the 2013 ASPEN guidelines for hospitalized obese patients. 11 It is important to note that 1 large observational study indicated a worse 60-day mortality when a hypocaloric feeding regimen (average caloric intake of 1000 kcal/d) was combined with a low protein intake (average protein intake of 46 g/d or 0.4 g/kg actual weight/d) for patients with class II (BMI of 35-39.9 kg/m 2 ) obesity. 41 This study 41 indicated that permissive underfeeding (whereby both calorie and protein intakes are allowed to be low) is potentially detrimental and that permissive underfeeding is entirely different from a hypocaloric high-protein nutrition regimen, whereby protein optimization is preserved.
Specialized Considerations for Hypocaloric, High-Protein Nutrition Therapy
Some subpopulations of hospitalized patients with obesity may require an adjustment in macronutrient design or protein intake. Subpopulations of interest include patients with class III obesity, older patients, and those with renal failure. To ascertain whether patients with class III obesity respond differently to nutrition therapy than less obese patients, Choban and Dickerson 12 performed a regression analysis of a larger database derived from previous studies 34, 35, 42 to examine the impact of protein intake on nitrogen balance for patients with class III obesity. The study revealed that ICU patients with class III obesity required ~2.5 g/kg IBW/d of protein to achieve nitrogen equilibrium compared with ~2 g/kg IBW/d for those with class I or II obesity. For non-ICU obese patients with class III obesity, a protein intake of ~1.8-1.9 g/kg IBW/d was necessary to achieve positive nitrogen equilibrium compared with ~1.7 g/ kg IBW/d for their less obese counterparts. Thus, the severity of obesity as well as the severity of illness influences protein requirements. The etiology for why those with class III obesity require more protein may be due to potential differences in anabolism due to insulin resistance 43 or inaccuracy of IBW as an estimate of total-body protein content for protein dosing 44 and requires further study.
One concern has been whether older hospitalized patients with obesity can be given a hypocaloric, high-protein nutrition diet. Despite similar protein and energy intakes, Liu and colleagues 39 found nitrogen balance to be lower in older patients than younger patients during hypocaloric, high-protein (Table 1 ). This study indicated that older patients, if given sufficient protein intake, can achieve a nitrogen balance analogous to younger patients during hypocaloric nutrition therapy.
One caveat for providing a higher protein intake in older patients is the increased risk for azotemia. Older patients may have greater baseline loss of muscle mass and lower source for creatinine and thus may have an occult decline in renal function that cannot be accurately quantitated by serum creatinine concentration. Although a decrease in glomerular filtration rate and renal functional reserve occurs with aging, 47 it is much less than necessary to elicit symptoms of renal failure. 48 Dickerson and colleagues 36 found that older patients' daily serum urea nitrogen concentrations were consistently greater and more variable than younger patients (mean, 30 ± 14 mg/dL vs 20 ± 9 mg/dL, respectively, P = .001) during hypocaloric, high-protein nutrition therapy. Four patients (12%) from the older patient population experienced a serum urea nitrogen concentration ≥60 mg/ dL, but none exhibited signs or symptoms of uremia or required hemodialysis. It was concluded that hypocaloric, high-protein nutrition therapy was safe and efficacious for use in older patients, but they were at greater risk for developing azotemia than younger patients and close monitoring is warranted. 36 Although current guidelines suggest higher protein intakes are safe for patients with renal or hepatic disease, 24 ceiling protein doses for these subpopulations have not been established. Patients with significant renal or hepatic disease may not be able to tolerate a large protein intake due to impending uremia or worsening encephalopathy. Protein intake may need to be adjusted based on change in serum urea nitrogen concentration, evidence of uremia, frequency and type of dialysis, or worsening of encephalopathy. Further research is necessary to define optimal calorie and protein intake for obese patients with significant advanced hepatic or renal disease.
Metabolic Monitoring
Monitoring should be designed to ensure the efficacy of the prescribed regimen as well as avoidance of potential complications associated with overfeeding. Fat weight loss should be viewed as a welcome secondary benefit and not the primary goal for hypocaloric, high-protein nutrition therapy. Metabolic monitoring of the obese patient has been previously reviewed in detail. 49 The presence of obesity and its associated comorbidities such as diabetes, hypoventilation syndrome, hyperlipidemia, nonalcoholic fatty liver disease, and congestive heart failure complicates the metabolic response to critical illness, particularly if the patient is already potentially experiencing detrimental physiologic consequences from excessive caloric intake. 49 In the ICU, despite its limitations, the most practical marker for assessing protein intake adequacy is nitrogen balance. More in-depth information on how to conduct, calculate, and interpret a nitrogen balance procedure has been described elsewhere. 50, 51 One author's (R.N.D.) current practice is to obtain a nitrogen balance soon after admission to the ICU to evaluate the extent of protein catabolism and then approximately weekly thereafter depending on the clinical course and severity of illness of the patient. During the acute phase of illness after trauma or surgery, if nitrogen equilibrium (about −4 to −5 g/d to +4 to +5 g/d) can be achieved with the goal protein intakes as previously outlined, the regimen is traditionally considered successful. The patient's clinical course, including evidence of wound healing, ventilator weaning, and time to transfer out of the ICU, should also be monitored.
The optimal duration for hypocaloric, high-protein nutrition therapy for the hospitalized patient with obesity is unknown. One author's (R.N.D.) empiric approach to this dilemma is to continue this therapy as long as the patient remains obese. As the patient's weight declines and approaches a normal body weight (or overweight without metabolic complications associated with obesity) during a prolonged hospital stay, caloric intake is liberalized in an attempt to arrest further weight loss and to maintain current body weight. Further study regarding the best approach for long-term management of hospitalized obese patients is warranted.
Conclusions
Hypocaloric, high-protein nutrition regimens are preferred for the hospitalized obese patient in an effort to achieve net protein anabolism or reduce catabolism and potentially avoid overfeeding-related complications in this "at-risk" population. Clinical outcomes are at least equivalent in patients given this type of nutrition therapy compared with eucaloric, high-protein feeding. It is recommended that an initial protein intake of 2 g/kg IBW/d be given to those with a BMI 30-39.9 kg/m 2 and 2.5 g/kg IBW/d for patients with a BMI ≥40 kg/m 2 . Patients should be provided a caloric intake of 22-25 kcal/kg IBW/d. A nitrogen balance determination may be used to evaluate adequacy of protein intake. Serial serum urea nitrogen concentrations should be closely monitored, especially in older patients or those with renal dysfunction. 
Discussion
Ryan T. Hurt: Are you a little surprised that we don't have more data in the area of high protein and hypocaloric feeding in obesity given how prevalent it is? One of the persistent problems has been delivery of high amounts of protein in the ICU, but we now have a number of commercial high-protein formulas. You have been a leader in this field and I would have expected others to have completed similar research given that 1 in 3 ICU patients is obese.
Roland N. Dickerson: I would estimate that a third of our patients are on a hypocaloric high-protein diet at this point in time in our practice. I agree we definitely do need a large randomized trial to fully evaluate feeding strategies in obese patients. I think we're getting better at delivering what we intend to deliver and the new formulas that are now available do help.
Beth Taylor: I've started looking at doing ultrasound measurements on the rectus femoral muscle. One of the interesting things I am finding is muscle depth is a lot larger in obese patients than their leaner counterparts. They do have much more adipose tissue, but they do have femoral muscle mass, and this may be something that we could follow in the future. Do you have any thoughts about the fact that with hypocaloric feeding, we really put them into a state of ketosis? Do you think there is any issue with utilizing the protein we're giving them?
Roland N. Dickerson: We don't really see ketosis in our patient population. Our earlier work with indirect calorimetry indicated that they were oxidizing fat, but the production of ketones was low. In terms of muscle mass assessment, it is both hard to measure but is really important. One of the points that needs to be emphasized is the fact that the sarcopenic obese patient is different than the patient who is not sarcopenic. Protein requirements may be different in these two distinct populations. How to best assess that in a practical way I think is difficult.
Beth Taylor: In the ICU, there are clinical situations that may add to your protein requirements. Patients may be on continuous renal replacement therapy or have an open abdomen, which will both contribute to losing protein. Based on the guidelines, we would make the highest recommendation for protein that is up to 2.5 g/kg ideal body weight/d. If you have these addition losses, would you go ahead and add protein in addition to the 2.5 g/kg ideal body weight/d? Roland N. Dickerson: When we have done that our nitrogen balance study and it comes back really negative when they are getting 2.5 g/kg ideal body weight/d, we have empirically increased our protein intake and cap it at 3 g/kg ideal body weight/d. This is because ideal body weight is only an estimate for protein dosing considerations. Someone that's a football player is going to be a lot more muscular than the patient who is elderly and uses an electronic scooter for daily mobility despite a similar BMI or ideal body weight. Should we go higher? I don't know the answer to that. Jayshil J. Patel: I would like to reinforce this notion that when we use BMI to identify obese patients, we run into trouble. We've already seen this in the critical care literature suggesting that obese have improved ICU outcomes. So you take a patient with a poor phenotype prior to entering the ICU saying that they are going to have improved outcomes. In addition, there are a number of logistic issues that are associated with ICU care of obese patients such as difficulty with placement of lines and intubation. Prior to moving forward with perspective randomized control trials, I think we need to do a better job of risk stratifying obese patients based on some type of evaluation for sarcopenia. I really think we need to use a radiographic or biochemical assessment for estimated lean body mass. We should use these measurements for lean body mass because if we are using ideal body weight, I worry that when we intend hypocaloric feeding, we end up with eucaloric feeding.
Roland N. Dickerson:
The basic obesity paradox in the ICU is somewhat confusing and conflicting. Those patients in the class I obesity range may have less metabolic complications from their obesity compared with those who are class II or III obesity. You are right that part of the inaccuracy is associated with the use of ideal body weight. Despite its limitations, that is why we use nitrogen balance to try to gauge where we are with adequacy of protein intake. And so, until we have something better, that's what we use. But I agree with you, we really need to have some way that we can assess what their muscle mass is to determine whether they're sarcopenic. I think that will really help guide therapy.
Peter J. M. Weijs: I just wanted to add on this topic that the literature is very consistent actually up to BMI 35 to 40 that there is a benefit, but it's only BMI. As soon as we measure muscle mass, it was very predictive and it did exclude BMI as a predictor.
Stephen A. McClave: As far as the obesity paradox, it is very clear when you separate the trauma patients from the medical or surgical ICU patients. There is a clear difference between those two patient populations. Trauma ICU patients do worse if you're obese as defined by BMI, and the medical ICU patients do better.
Daren K. Heyland: I am a little nervous about guidelines recommendations that are based on two small randomized controlled trials (RCTs) where there are only 13 ICU patients and yet we have millions of obese people that we're managing this way. I appreciate that you're asking for a large RCT to really evaluate impact on more distal clinical outcomes. The question I have relates to the conversation we're having about not all ICU obese patients are the same. But if we step back a little bit, I think there's almost like a Nutrition Risk in Critically Ill (NUTRIC)-like approach here that could happen. Because there's going to be other determinants to outcome as it pertains to obesity that are independent of body mass index. We just followed a large cohort of 800 ICU patients for a year looking at their BMI. It was measured as a covariate, but their physical performance at a year was largely determined by their physical performance and frailty scale at baseline. Obese patients have variability in their baseline physical performance and that might be different than what you measure as a body composition because body mass isn't always the same as function. Is there a way of conceptually thinking through all the determinants to outcome and nutritional interventions in obese patients? I agree with earlier comments that it is not just BMI. I think sarcopenia begins to narrow it down, but that's not the end of the story either.
Roland N. Dickerson: I agree with your statements and I think we definitely need better and larger studies that focus on improved outcome measures.
Evan Berk: I don't know if anyone here is familiar with the Edmonton Obesity Staging System. It's a way to classify obesity based on a number of variables, including physical and mental factors. There is some really interesting research that has looked at mortality based on people's BMI, and when they evaluated patients using the Edmonton Obesity Staging System, it was a much better predictor of mortality. This might be something to consider when designing your studies.
